A 68-year-old man with myasthenia gravis presents to the emergency department with acute respiratory distress, ptosis, and generalized muscle weakness. He has been on pyridostigmine 60 mg QID for the past 2 years. His wife reports he ran out of medication 3 days ago. On examination, he has severe bulbar weakness and vital capacity of 1.2 L. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context: Myasthenic Crisis This patient presents with **myasthenic crisis** — acute, life-threatening respiratory and bulbar muscle weakness in a patient with myasthenia gravis who has been off anticholinesterase medication. ### Key Features Indicating Crisis **Key Point:** Vital capacity < 1.5 L, severe bulbar weakness (risk of aspiration), and respiratory distress are hallmarks of myasthenic crisis requiring immediate airway protection. ### Management Algorithm ```mermaid flowchart TD A[Myasthenic Crisis Suspected]:::outcome --> B{Respiratory Compromise?}:::decision B -->|Yes: VC < 1.5 L, RR > 30| C[Secure Airway Immediately]:::urgent B -->|No: Stable respiratory status| D[Supportive Care + IV Immunoglobulin]:::action C --> E[Intubate & Mechanically Ventilate]:::action E --> F[Initiate IVIG or Plasma Exchange]:::action D --> G[Monitor VC q4h]:::action ``` ### Why Airway Security is First 1. **Respiratory failure risk**: VC 1.2 L indicates severe respiratory compromise (normal >2.5 L) 2. **Bulbar weakness**: Ptosis + generalized weakness = aspiration risk 3. **Time-critical**: Deterioration can be rapid; prophylactic intubation prevents emergent cricothyrotomy **High-Yield:** In myasthenic crisis, **airway management supersedes pharmacotherapy**. Do not delay intubation waiting for drug response. ### Role of Anticholinesterases in Crisis **Warning:** Anticholinesterases (pyridostigmine, neostigmine) are **contraindicated** in acute crisis because: - They worsen bronchospasm and secretions - They can precipitate cholinergic crisis (muscarinic overdose) - They do not address the underlying immune pathology **Clinical Pearl:** Edrophonium (Tensilon) is a diagnostic agent for differentiating myasthenic vs. cholinergic crisis; it is NOT a treatment in acute crisis and carries risk of cardiac arrhythmia. ### Definitive Treatment After Stabilization Once airway is secured: - **Intravenous immunoglobulin (IVIG)** 2 g/kg over 3–5 days, OR - **Plasma exchange** (5 exchanges over 7–10 days) - Both are equally effective; choice depends on availability and comorbidities [cite:Harrison 21e Ch 385]